Biotech & Pharma

STAT+: Pharma lobbyists focus on a surprising new target: the FDA

28 sec read7 views0 listens

The pharmaceutical industry is capitalizing on the Trump administration's increased political influence over the FDA, a traditionally insulated agency, allowing for unprecedented lobbying efforts. This shift alters the dynamic between the industry and regulatory decisions, previously considered untouchable, now making it easier to sway FDA policies. Content creators should note this development as it highlights a significant change in how pharmaceutical regulations are influenced and communicated.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Legal & Policy8 hours ago25 sec read

What A Torn Rotator Cuff Can Teach Us About Legal Business Development

A business development coach shares lessons from his recovery from a torn rotator cuff, drawing parallels between physical rehabilitation and building a successful law practice. He emphasizes that achieving goals requires sacrifice, following a struc...

Ali Nemati

Biotech & Pharma11 hours ago23 sec read

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Aprea Therapeutics is accelerating enrollment in its Phase I trial of APR-1051, a WEE1 kinase inhibitor, after observing early signs of clinical activity. This expansion aims to gather more data on the drug's efficacy and safety, particularly for pat...

Ali Nemati

Biotech & Pharma11 hours ago29 sec read

The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates

Cindy Cheng, PhD, will discuss the development of dual-payload antibody-drug conjugates (dp-ADCs) to enhance efficacy and overcome drug resistance in cancer treatments. This innovation is crucial for biotech and pharma developers aiming to improve th...

Ali Nemati